DDIT3 and lymphoma: In an ongoing study, the combination of R-CHOP (GCB subtype) plus durvalumab or lenalidomide plus R-CHOP (R2-CHOP) (non-GCB subtype) followed by durvalumab consolidation for up to 12 months is under evaluation in patients with previously untreated DLBCL and high-risk features, mostly with double-/triple-hit lymphoma [54].